Summary of p21 promoter methylation in various cell lines and primary tumors
. | Methylation (%) . | Method used . | Reference . |
|---|---|---|---|
| Present study | MSP + BGS | NA | |
| Tumor cell lines | |||
| Burkitt lymphoma | 2/7 (29) | ||
| Hodgkin disease | 0/6 | ||
| Leukemia | 0/4 | ||
| Nasopharyngeal Ca | 0/10 | ||
| Esophageal Ca | 0/16 | ||
| Breast Ca | 0/3 | ||
| Laryngeal Ca | 0/1 | ||
| Lung Ca | 0/1 | ||
| Colorectal Ca | 0/5 | ||
| Gastric Ca | 0/1 | ||
| Hepatocellular Ca | 0/2 | ||
| Cervical Ca | 0/2 | ||
| Primary tumors (geographic origin) | |||
| Burkitt lymphoma (Africa) | 2/8 (25) | ||
| Diffuse large B-cell lymphoma (United Kingdom) | 0/13 | ||
| Follicular lymphoma (United Kingdom) | 0/6 | ||
| Mantle cell lymphoma (United Kingdom) | 0/4 | ||
| Posttransplant lymphoma (United States) | 0/13 | ||
| Anaplastic large cell lymphoma (United Kingdom) | 0/4 | ||
| Nasal NK/T cell lymphoma (Hong Kong) | 1/18 (6) | ||
| Hodgkin disease (United States, United Kingdom) | 0/31 | ||
| Other types of lymphoma (United Kingdom) | 0/3 | ||
| Nasopharyngeal Ca (Taiwan, Singapore) | 0/25 | ||
| Esophageal Ca (Hong Kong) | 0/35 | ||
| Breast Ca (Singapore) | 0/21 | ||
| Gastric Ca (United Kingdom) | 0/5 | ||
| Lung Ca (Singapore) | 0/1 | ||
| Normal PBMC (Singapore) | 0/12 | ||
| Normal tissues (lymph node, breast, placenta, pancreas) | 0/10 | ||
| Literature review | |||
| Cell lines and primary tumors | |||
| Hematopoietic tumor cell lines | 0/14 | COBRA | 4 |
| Central nervous system lymphoma | 0/18 | MSP | 5 |
| Acute lymphocytic leukemia | 51/124 (41) | RE/PCR | 2 |
| Acute lymphocytic leukemia | 0/31 | COBRA + MSP | 3 |
| Gastric lymphoma | 4/13 (31) | MSP | 9 |
| Instestinal lymphoma | 0/14 | MSP | 9 |
| Lung Ca cell lines | 2/16 (13) | COBRA | 6 |
| Colorectal Ca cell lines | 0/10 | COBRA | 4 |
| Gastric Ca cell lines | 0/15 | COBRA | 4,8 |
| Hepatocellular Ca cell lines | 0/5 | COBRA | 4 |
| Pancreatic Ca cell lines | 0/2 | COBRA | 4 |
| Prostate Ca | 2/16 (13) | MSP | 7 |
| Rhabdomyosarcoma cell lines and tumors | 15/31 (48) | RE/Southern blot | 1 |
. | Methylation (%) . | Method used . | Reference . |
|---|---|---|---|
| Present study | MSP + BGS | NA | |
| Tumor cell lines | |||
| Burkitt lymphoma | 2/7 (29) | ||
| Hodgkin disease | 0/6 | ||
| Leukemia | 0/4 | ||
| Nasopharyngeal Ca | 0/10 | ||
| Esophageal Ca | 0/16 | ||
| Breast Ca | 0/3 | ||
| Laryngeal Ca | 0/1 | ||
| Lung Ca | 0/1 | ||
| Colorectal Ca | 0/5 | ||
| Gastric Ca | 0/1 | ||
| Hepatocellular Ca | 0/2 | ||
| Cervical Ca | 0/2 | ||
| Primary tumors (geographic origin) | |||
| Burkitt lymphoma (Africa) | 2/8 (25) | ||
| Diffuse large B-cell lymphoma (United Kingdom) | 0/13 | ||
| Follicular lymphoma (United Kingdom) | 0/6 | ||
| Mantle cell lymphoma (United Kingdom) | 0/4 | ||
| Posttransplant lymphoma (United States) | 0/13 | ||
| Anaplastic large cell lymphoma (United Kingdom) | 0/4 | ||
| Nasal NK/T cell lymphoma (Hong Kong) | 1/18 (6) | ||
| Hodgkin disease (United States, United Kingdom) | 0/31 | ||
| Other types of lymphoma (United Kingdom) | 0/3 | ||
| Nasopharyngeal Ca (Taiwan, Singapore) | 0/25 | ||
| Esophageal Ca (Hong Kong) | 0/35 | ||
| Breast Ca (Singapore) | 0/21 | ||
| Gastric Ca (United Kingdom) | 0/5 | ||
| Lung Ca (Singapore) | 0/1 | ||
| Normal PBMC (Singapore) | 0/12 | ||
| Normal tissues (lymph node, breast, placenta, pancreas) | 0/10 | ||
| Literature review | |||
| Cell lines and primary tumors | |||
| Hematopoietic tumor cell lines | 0/14 | COBRA | 4 |
| Central nervous system lymphoma | 0/18 | MSP | 5 |
| Acute lymphocytic leukemia | 51/124 (41) | RE/PCR | 2 |
| Acute lymphocytic leukemia | 0/31 | COBRA + MSP | 3 |
| Gastric lymphoma | 4/13 (31) | MSP | 9 |
| Instestinal lymphoma | 0/14 | MSP | 9 |
| Lung Ca cell lines | 2/16 (13) | COBRA | 6 |
| Colorectal Ca cell lines | 0/10 | COBRA | 4 |
| Gastric Ca cell lines | 0/15 | COBRA | 4,8 |
| Hepatocellular Ca cell lines | 0/5 | COBRA | 4 |
| Pancreatic Ca cell lines | 0/2 | COBRA | 4 |
| Prostate Ca | 2/16 (13) | MSP | 7 |
| Rhabdomyosarcoma cell lines and tumors | 15/31 (48) | RE/Southern blot | 1 |
NA indicates not applicable; Ca, carcinoma; COBRA, combined bisulfite restriction analysis; and RE, restriction enzyme digestion.